BRISBANE, Calif. — September 24, 2026

Annexon, Inc. announced that it will present two oral presentations on vonaprument at The Retina Society 59th Annual Scientific Meeting in Los Angeles, highlighting Phase 2 vision-protection findings and baseline characteristics from the ongoing Phase 3 ARCHER II trial in geographic atrophy (GA). The presentations will include a post hoc analysis of Phase 2 ARCHER data and an assessment of participant characteristics in ARCHER II, which is designed to evaluate whether vonaprument can protect visual function in patients with GA. Month 15 results from ARCHER II are expected in the fourth quarter of 2026.

ARCHER II Evaluates Vonaprument for Vision Protection

ARCHER II is a global Phase 3 trial enrolling 659 patients with GA, with confirmed best-corrected visual acuity (BCVA) loss of at least 15 letters serving as the primary endpoint through Months 15 and 24. The study was designed to replicate findings from the completed Phase 2 ARCHER trial across a broad GA population. Annexon said the baseline clinical characteristics between the Phase 2 and Phase 3 populations were consistent, supporting the company’s development strategy for evaluating vonaprument across a diverse patient population. ARCHER II is being conducted under a global registration strategy established with U.S. and European regulators.

Phase 2 Data Support Ongoing ARCHER II Program

The presentation “Vision Outcomes in Eyes with Subfoveal RPE Lesions in Geographic Atrophy: A Post Hoc Analysis of the Phase 2 ARCHER Trial” will examine visual outcomes in a specific subgroup of GA patients. According to Annexon, the Phase 2 ARCHER study showed time- and dose-dependent protection from vision loss, including outcomes based on confirmed BCVA loss of at least 15 letters, as well as preservation of ellipsoid-zone retinal structure across multiple measures. The company reported that vonaprument was generally well tolerated through Month 12, with no increase in choroidal neovascularization rates versus sham and no retinal vasculitis events. These Phase 2 findings are being evaluated prospectively in the ongoing Phase 3 program.

Advertisement

cGxPJobs Banner

Vonaprument Targets C1q in Geographic Atrophy

Vonaprument, formerly known as ANX007, is an investigational antigen-binding fragment designed to selectively inhibit C1q, the initiating molecule of the classical complement pathway. Administered by intravitreal injection, the therapy is designed to block classical complement-driven neuroinflammation while preserving the lectin and alternative complement pathways. Annexon is developing vonaprument as a potential targeted therapy intended to protect photoreceptor cells and retinal function in GA. The candidate has received FDA Fast Track designation and EMA PRIME designation for GA. ARCHER II remains an ongoing pivotal study, and its future clinical value will depend on the results of the prespecified Phase 3 endpoints.

Source :Annexon, press release